^
    CANCER:

    Renal Cell Carcinoma





    Show legend
    Group by Gene:
    Include preclinical:

    bevacizumab-awwb
    bevacizumab-tnjn
    bevacizumab
    		0
    VEGF-A inhibitor
    bevacizumab-adcd
    Krabeva (bevacizumab biosimilar)
    bevacizumab-bvzr
    bevacizumab-maly
    Aybintio (bevacizumab biosimilar)
    nivolumab
    PD1 inhibitor
    		1
    PD1 inhibitor
    pembrolizumab
    toripalimab-tpzi
    dostarlimab-gxly
    cabozantinib tablet
    		2
    Multi-tyrosine kinase inhibitor
    pazopanib
    cabozantinib capsule
    midostaurin
    mTOR inhibitor
    		3
    mTOR inhibitor
    everolimus
    temsirolimus
    4
    IFNα stimulant, VEGF-A inhibitor
    Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
    bevacizumab + pegylated interferon α -2a
    pembrolizumab + axitinib
    		5
    VEGFR inhibitor, PD1 inhibitor
    toripalimab-tpzi + axitinib
    sintilimab + axitinib
    6
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + cabozantinib tablet
    7
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    8
    c-MET inhibitor
    c-MET inhibitor
    savolitinib
    9
    VEGFR inhibitor, PD-L1 inhibitor
    avelumab + axitinib
    10
    VEGF-A inhibitor, EGFR inhibitor
    bevacizumab + erlotinib
    11
    HIF-2α inhibitor
    belzutifan
    12
    VEGFR inhibitor
    VEGFR inhibitor
    axitinib
    13
    EGFR inhibitor
    erlotinib
    14
    ALK inhibitor
    crizotinib
    alectinib
    PD-L1 inhibitor
    		15
    PD-L1 inhibitor
    atezolizumab
    avelumab
    16
    AXL inhibitor, GAS6 inhibitor
    AVB-500
    17
    HLA G-targeted CAR-T immunotherapy
    IVS-3001
    18
    CD70-targeted CAR-T immunotherapy
    ALLO-316
    19
    PD1 inhibitor, Multi-tyrosine kinase inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab + cabozantinib tablet
    20
    PARP inhibitor
    olaparib
    talazoparib
    21
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    22
    Tubulin inhibitor
    vinblastine
    23
    VEGF-A inhibitor, PI3Kγ inhibitor, Bcl2 inhibitor, Tubulin inhibitor
    bevacizumab + albumin-bound paclitaxel + IPI-549
    24
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    25
    PD-L1 inhibitor, c-MET inhibitor
    durvalumab + savolitinib
    26
    PD1 inhibitor, IDO1 inhibitor
    nivolumab + BMS-986205
    pembrolizumab + INCB024360
    27
    FGFR inhibitor
    ABSK091
    28
    HDAC inhibitor, Multi-tyrosine kinase inhibitor
    pazopanib + CG-781
    29
    VEGFR inhibitor, mTOR inhibitor
    temsirolimus + axitinib
    30
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    31
    PRMT5 inhibitor
    AMG 193
    32
    ALK inhibitor, Multi-tyrosine kinase inhibitor
    crizotinib + pazopanib
    33
    HDAC inhibitor
    vorinostat
    34
    HIF-2α antagonist
    MK-3795
    35
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    36
    Immunotherapy
    Immunotherapy
    37
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    38
    Glutamate inhibitor
    Glutamate inhibitor
    39
    VEGF inhibitor
    VEGF inhibitor
    40
    Immunotherapy, Tyrosine kinase inhibitor
    Immunotherapy + Tyrosine kinase inhibitor
    41
    VEGFR inhibitor, Immunotherapy
    Immunotherapy + VEGFR inhibitor
    42
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    43
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    44
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib
    45
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, mTOR inhibitor, c-KIT inhibitor, PDGFR α antagonist
    everolimus + lenvatinib
    46
    VEGFR-1 inhibitor, VEGFR-2 inhibitor, VEGFR-3 inhibitor
    tivozanib
    47
    CD122 agonist, IL-2 stimulant
    aldesleukin
    48
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor, FLT3 inhibitor
    ABT-869
    49
    PD-L1 inhibitor, VEGF-A inhibitor, PI3Kγ inhibitor
    bevacizumab + atezolizumab + IPI-549
    50
    PD-L1 inhibitor, VEGF-A inhibitor
    bevacizumab + atezolizumab
    51
    AXL inhibitor, Multi-tyrosine kinase inhibitor, GAS6 inhibitor
    cabozantinib tablet + AVB-500
    52
    VEGFR-2 inhibitor, c-MET inhibitor
    GSK1363089
    53
    TIM-1-targeted antibody-drug conjugate, Microtubule inhibitor
    CDX-014
    54
    TGM2 inhibitor
    MD102
    55
    UCHL1 inhibitor, Androgen receptor inhibitor
    enzalutamide capsule + 6RK73
    56
    FGFR4 inhibitor
    BLU 9931
    57
    VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
    sunitinib + pazopanib
    58
    Ionizing radiation emitter, CD37 inhibitor
    177Lu-satetraxetan-lilotomab
    59
    HER3 inhibitor, α radiation emission
    Ac-225 ErbB3 targeted radiotherapy
    60
    MCL1 inhibitor
    PRT1419
    61
    pan-RAF inhibitor, Hyaluronic acid synthase inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + 4-methylumbelliferone
    62
    PRC2 inhibitor
    MRTX2219
    63
    AKT inhibitor
    GSK690693
    64
    NF-κB inhibitor, SYK inhibitor
    BAY-61-3606
    65
    MEK2 inhibitor, MEK1 inhibitor
    U0126
    66
    pan-RAF inhibitor, VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
    sorafenib + sunitinib
    67
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    68
    CDH6-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    CUSP06
    69
    RAC1 inhibitor
    NSC23766
    70
    CYP17A1 inhibitor
    abiraterone acetate
    71
    DNA synthesis inhibitor
    cisplatin
    72
    ATR inhibitor
    M6620
    No biomarker
    MET amplification
    MET mutation
    MET fusion
    MET expression
    PD-L1 expression
    PD-L1 underexpression
    PD-L1 overexpression
    PBRM1 mutation
    PBRM1 negative
    PBRM1 deletion
    PBRM1 overexpression
    PBRM1 underexpression
    MTOR mutation
    KDR rs2071559
    KDR C482R
    MTOR Q2223K
    MTOR overexpression
    KDR expression
    KDR overexpression
    RNASET2 overexpression
    FLT1 rs9554320
    FLT1 expression
    FLT1 overexpression
    HLA-G positive
    ARID1A mutation
    ROBO3 mutation
    AXL-L
    AXL expression
    AXL overexpression
    PD-1 expression
    VHL mutation
    ALK rearrangement
    HMOX1-L
    TSC1 deletion
    TSC1 mutation
    HMOX1 expression
    VCP-TFE3 fusion
    FH mutation
    FH deletion
    TSC2 mutation
    TSC2 H1620R + TSC2 Y1650C
    HGF expression
    HGF-L
    TFE3 translocation
    FH negative
    HGF elevation
    VHL promoter methylation
    VHL deletion
    PD-1 elevation
    KDM5C mutation
    MSI-H/dMMR
    BRCA1 mutation
    BRCA2 mutation
    KIM1 expression
    FLCN mutation
    HDAC2 expression
    ERVE-4 expression
    HAVCR2 expression
    SPP1-L
    CXCL8-L
    IL6-L
    IL18 expression
    ANGPT2 expression
    TIMP1 expression
    CSF1 expression
    VEGFA expression
    CXCL9 expression
    IL18BP expression
    SYNE1 mutation
    CDKN2A mutation
    CEACAM1 overexpression
    CXCL10 overexpression
    CA9 expression
    CD31 expression
    GNAQ mutation
    IKZF2-L
    PDGFRA expression
    CD8 expression
    HIF1A expression
    LRP1B mutation
    ELTD1 expression
    BAP1 negative
    IL6R L
    IL6ST elevation
    TFEB translocation
    EWSR1-POU5F1 fusion
    KMT2C mutation
    LDH elevation
    CTLA4 promoter hypomethylation
    NANOGNB mutation
    PARP1 underexpression + PBRM1 mutation
    PTTG1 overexpression
    TNFRSF9 elevation
    PD-L1 expression + CD14 positive
    LAG3 positive + CD4 positive
    TNFRSF9 positive + CD8 positive
    TNFRSF9 positive + CD4 positive
    NF2 mutation
    FOLH1 overexpression
    KHDRBS1 overexpression
    PECAM1 underexpression
    CD3G overexpression
    NCAM1 overexpression
    CD4 underexpression
    ISLR overexpression
    AXL elevation + GAS6 elevation
    PYCR1 underexpression
    TNFRSF18-H
    MTAP deletion
    TLR3 overexpression
    WDR72 overexpression + PBRM1 mutation
    WDR72 overexpression
    PBRM1 mutation + SETD2 mutation
    TERT promoter mutation
    BRAF mutation
    miR-138 underexpression + miR-497 overexpression
    SETD2 mutation + TP53 mutation
    TERT overexpression
    KIM1 elevation
    IL6 elevation
    BAP1 mutation
    CXCL10 elevation
    CDKN2A deletion
    VEGFA elevation
    SETD2 mutation
    BAP1 deletion
    SETD2 deletion
    VEGFA overexpression
    CXCL8 elevation
    AP positive signature
    T-cell-inflamed GEP signature
    Immune response prediction signature
    IFNG gene signature overexpression
    DDR
    BONSAI high signature
    Low MLR
    Low NLR
    SMARCA4 mutation
    KDM6A mutation
    CCNE1 amplification
    CTBP1 deletion
    ACRBP amplification
    GNAS amplification
    LRP10 deletion
    SULT1A3 amplification
    UGT1A9 expression
    ADCYAP1 deletion
    TP53 mutation
    PAI1 elevation
    AXL overexpression + PD-L1 expression
    NT5E overexpression
    CXCL13 elevation
    TNFSF13B elevation
    TMB-H
    CD44 expression
    CD44 positive
    IL13RA2 overexpression
    CXCR4 overexpression
    TGM2 overexpression
    IL7 elevation
    CXCL12 elevation
    PRCC-TFE3 fusion
    VEGFB overexpression
    PGF overexpression
    PTEN deletion
    VEGFC underexpression
    DDX39B overexpression
    PDGFA underexpression
    FLT4 overexpression
    CXCL11 elevation
    VEGFD overexpression
    MTA2 overexpression
    CD27 overexpression
    SPI1 overexpression
    HLA-A*03
    CD276 expression
    CD70 expression
    TERC overexpression
    DKC1 overexpression
    FGFR4 amplification
    PLK1 overexpression
    MCAM overexpression
    ERBB3 expression
    EPAS1 G323E
    EPAS1 S304M
    TP53 expression
    EPAS1 overexpression
    FGFR1 overexpression
    LAG3 expression
    BBOX1 underexpression
    CCL4 elevation
    AR-V7 positive
    CDH6 expression
    KAT6A-NRG1 fusion
    Chr del(9)(p21.3)
    HAS3 expression
    DAPK1 underexpression
    miR-155 underexpression